[Coronary atherosclerosis and vascular endothelial dysfunction].
Nishinaga
Masanori
M
Department of Medicine and Geriatrics, Kochi Medical School.
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001120:Arginine / Q000627:therapeutic use; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D003324:Coronary Artery Disease / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000166:cytology / Q000473:pathology / Q000503:physiopathology*; D011464:Epoprostenol; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009569:Nitric Oxide; D011379:Prognosis; D012307:Risk Factors; D018180:Thrombomodulin; D010959:Tissue Plasminogen Activator; D014841:von Willebrand Factor
D000806:Angiotensin-Converting Enzyme Inhibitors; D000975:Antioxidants; D015415:Biomarkers; D015815:Cell Adhesion Molecules; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018180:Thrombomodulin; D014841:von Willebrand Factor; D009569:Nitric Oxide; D001120:Arginine; D011464:Epoprostenol; D010959:Tissue Plasminogen Activator